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Background/aim: To investigate the variations in the recurrence patterns of stage IB cervical cancer according to lymph node
involvement.
Materials and methods: We reviewed the medical records of 170 patients who had undergone type III radical hysterectomy and
systematic lymphadenectomy from 1993 to 2007.
Results: Among the patients in the study group, 115 did not have lymph node metastases, whereas 55 did. A total of 27 patients
developed recurrences. Twelve were in the lymph node-negative group, and 15 were in the lymph node-positive group. The recurrence
rate was higher in lymph node-positive group (27.3% versus 10.4%, P = 0.011). The recurrence pattern was not affected by lymph
node involvement. However, distant recurrence was more common in the lymph node-positive group (53.3% versus 25%, P = 0.137).
Additionally, distant failure was observed only in the patients in the lymph node-negative group who received adjuvant radiotherapy. In
this group, 3 patients who did not receive adjuvant radiotherapy developed recurrences only in the pelvic region.
Conclusion: The presence of lymph node involvement in stage IB cervical cancer does not affect the site of recurrence. However, distant
recurrence was more frequent in the lymph node-positive group.
Key words: Cervical carcinoma, lymph node metastasis, recurrence

1. Introduction
Carcinoma of the cervix uteri is the second most common
cancer and the third most common cause of cancer
deaths in women worldwide (1,2). The definitive primary
treatment for patients with early-stage disease consists of
radiation therapy or radical hysterectomy with pelvic and/
or paraaortic lymph node dissection (3). Knowledge about
prognosis and recurrence is critical for the management of
early-stage cervical cancer. Lymph node involvement is an
important risk factor for recurrence in patients with earlystage cervical cancer. The recurrence rate in lymph nodenegative patients was 10% and the 5-year survival rate
ranged from 85%–90%. In contrast, the recurrence rate
in lymph node-positive patients was 27% and the 5-year
survival rate ranged from 20% to 74% depending on the
number of nodes that were involved and the location and
size of the metastases (4–6).
In this retrospective study, we analyzed the variations
in the recurrence patterns of stage IB cervical cancer
* Correspondence: isin.ureyen@gmail.com
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according to lymph node involvement. These data may
improve the management of early-stage cervical cancer to
reduce the risk of recurrence and predict the recurrence
patterns of early-stage cervical cancer.
2. Materials and methods
The medical records of patients diagnosed with stage
IB cervical cancer and who were treated with type III
radical hysterectomy, bilateral salpingo-oophorectomy,
or systemic pelvic and paraaortic lymphadenectomy
from January 1993 to December 2007 were evaluated
retrospectively. The complete pathological data of 170
patients were evaluated. Patients who received neoadjuvant
chemotherapy were excluded because chemotherapy is
known to improve surgical pathological results (7).
All of the patients were evaluated by rectovaginal
examination under general anesthesia, computerized
tomography of the upper abdomen and pelvic magnetic
resonance imaging, or intravenous pyelography. Clinical
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staging was performed according to the International
Federation of Gynecology and Obstetrics 1988 criteria.
The tumor size that was defined in the study was the
greatest tumor diameter as determined by rectovaginal
examination under general anesthesia.
High-risk patients received postoperative radiotherapy.
Up until 2001, the criterion for postoperative adjuvant
radiotherapy was the presence of at least 1 of the
major risk factors (positive lymph nodes, parametrial
involvement, the presence of a tumor within the surgical
margins, and a tumor size ≥4 cm) or 2 of the minor
risk factors (lymphovascular space involvement [LVSI],
stromal invasion of ≥½, a tumor size of 2–4 cm, and
3 or more lymph nodes with microscopic metastasis).
After 2001, only patients who had positive lymph nodes
and/or parametrial involvement and/or a tumor within
the surgical margins received adjuvant radiotherapy.
Radiotherapy was administered alone or in combination
with chemotherapy (concurrent radiochemotherapy
[CCRT]) as the initial treatment. Adjuvant radiotherapy
had been the sole treatment for cervical cancer until the
National Cancer Institute announced in 1999 that CCRT
was accepted as a standard therapy. Radiotherapy was
administered by the Department of Radiation Oncology.
External radiotherapy was administered using the 4-field
box technique with 6–18 MV photon beams at a total dose
of 4500–5000 cGy with conventional daily fractionation. In
patients with paraaortic lymph node metastasis, 45 Gy of
paraaortic radiotherapy was added. In cases with surgical
margins that were close to the vagina, 21 Gy of high-dose
vaginal brachytherapy was applied in 3 fractions. Vaginal
brachytherapy was applied 0.5 cm below the vaginal
mucosa, and the upper 4 cm of the vagina was treated.
In the CCRT group, weekly cisplatin was given
to the patients during radiotherapy. The calculated
cisplatin dosage was infused in 1000 mL of normal saline
solution over 1 h with 150 mL of 20% mannitol following
premedication. Before chemotherapy was given, the
following criteria were met: 1) adequate bone marrow
function (leukocytes ≥3000/mL, neutrophils ≥1500/mL,
platelets ≥100,000/mL, and hemoglobin ≥10 mg/dL); 2)
adequate hepatic function (total bilirubin, AST, and ALT
less than twice the normal levels); and 3) sufficient renal
function (a glomerular filtration rate of ≥60 mL/min).
Patients were evaluated every 3 months for the first
2 years, every 6 months for the following 3 years, and
annually thereafter. Follow-up included rectovaginal
examination, a Pap smear test, abdominal sonography, a
complete blood count, and serum biochemistry.
The presence of a single region of recurrence was
defined as an isolated recurrence. Disease-free survival
(DFS) was defined as the time interval between the
initiation of treatment and recurrence. Overall survival

(OS) was defined as the time interval between the initiation
of treatment and death.
Chi-squared and ANOVA table tests were used to
analyze the differences between the mean values and the
percentages. The statistical analyses were performed using
SPSS 17.0 for Windows (SPSS Inc., USA), and statistical
significance was considered at P < 0.05.
3. Results
We identified 170 patients who were diagnosed with stage
IB cervical cancer and who were treated with type III
radical hysterectomy and bilateral pelvic and paraaortic
lymphadenectomy. Lymph node involvement was
determined in 55 patients. The remaining 115 patients of
the study group did not have lymph node metastases.
The mean age of the study group was 53.4 years with
a range of 34–80 years, and the mean tumor size was
28.5 mm with a range of 5–75 mm. Although tumor
size was measured as 5 mm for 4 patients, these patients
were accepted as having stage IB1 disease according to
biopsy results. Lymph node status, patient characteristics,
distribution of surgical and pathologic risk factors, and
differences between the groups are shown in Table 1.
Lymph node involvement was higher in stage IB2 cervical
cancer and the tumor size was larger in the lymph nodepositive group (P = 0.003 and P = 0.002, respectively).
LVSI was more significant in patients with lymph node
involvement (P < 0.001). Age, cell type, grade, depth of
stromal invasion, presence of parametrial involvement,
surgical margin positivity, ovarian metastasis, number of
lymph nodes that were removed, and median follow-up
time were similar among the 2 groups (Table 1). However,
ovarian metastases were 4 times higher in the lymph nodepositive group.
All of the patients with positive lymph nodes received
adjuvant radiotherapy, whereas 50.4% of the patients with
negative lymph nodes received this therapy (P < 0.0001).
The groups were similar regarding the type of adjuvant
radiotherapy (only radiotherapy or CCRT). CCRT was
administered to 66% and 58% of the patients with positive
lymph nodes and negative lymph nodes, respectively
(P = 0.410). We could not obtain information about the
type of adjuvant radiotherapy in 3 patients in the lymph
node-negative group and in 5 patients in the lymph nodepositive groups.
The lymph node status could not be used to predict
distant failure when the recurrence site was adjusted by
the lymph node status and the administration of adjuvant
radiotherapy (Table 2). Distant failure was observed in
33.3% (3/9 patients with recurrence) of the patients with
negative lymph nodes who received radiotherapy, whereas
distant failure was observed in 53.3% (8/15 patients
with recurrence) of the patients with positive lymph

845

ÜREYEN et al. / Turk J Med Sci
Table 1. The distribution of characteristics and surgical pathological risk factors.
Mean (range) / n (%)

Parameter

P

Lymph node-negative

Lymph node-positive

Age

52.9 (34–76, median: 52)

54.3 (34–80, median: 52)

0.374

Tumor size (mm)

27.2 (5–45, median: 30)

31.2 (10–75, median: 30)

0.002

IB1

109 (94.8)

44 (80)

IB2

6 (5.2)

11 (20)

Squamous

91 (79.1)

43 (78.2)

Adenocarcinoma

17 (14.8)

9 (16.4)

Adenosquamous

7 (6.1)

3 (5.5)

1

14 (12.2)

8 (14.5)

2

87 (75.7)

41 (74.5)

3

14 (12.2)

6 (10.9)

No

23 (20)

6 (10.9)

Yes

92 (80)

49 (89.1)

Negative

91 (98.9)

47 (95.9)

Positive

1 (1.1)

2 (4.1)

Negative

107 (93)

49 (89.1)

Positive

8 (7)

6 (10.9)

Negative

63 (54.8)

9 (16.4)

Positive

52 (45.2)

46 (83.6)

≤1/2

50 (43.5)

15 (27.3)

>1/2

65 (56.5)

40 (72.7)

Negative

19 (86.1)

43 (78.2)

Positive

16 (13.9)

12 (21.8)

No

57 (49.6)

-

Yes

58 (50.4)

55 (100)

Only radiotherapy

23 (41.8)

17 (34)

Concurrent radiochemotherapy

32 (58.2)

33 (66)

Negative

115 (100)

-

Positive

-

55 (100)

Stage
Cell type

Grade
Bilateral salpingo-oophorectomy
Ovarian metastasis
Surgical margin invasion
Lymphovascular space invasion
Stromal invasion
Parametrial invasion
Adjuvant radiotherapy
Applied adjuvant
radiotherapy
Lymph node metastasis

0.003
0.956

0.897
0.140
0.200
0.380
<0.001
0.100
0.194
<0.0001
0.410
-

Number of lymph nodes removed

51.9 (13–113, median: 47)

54.2 (16–102, median: 52)

0.520

Number of metastatic lymph nodes

-

3.8 (1–19, median: 2)

-

Isolated pelvic

-

47 (85.5)

Isolated paraaortic

-

2 (3.6)

Pelvic + paraaortic

-

6 (10.9)

Negative

103 (89.6)

40 (72.7)

Positive

12 (10.4)

15 (27.3)

25.2 (4–66, median: 11)

18.8 (3–51, median: 14)

Isolated pelvic

9 (7.8)

7 (12.7)

Isolated pulmonary

1 (0.99)

2 (3.6)

Pulmonary + upper abdomen

-

1 (1.8)

Pelvic + upper abdomen + pulmonary

-

2 (3.6)

Isolated bone

1 (0.9)

1 (1.8)

Bone + brain

1 (0.9)

-

Bone + pulmonary

-

1 (1.8)

Bone + supraclavicular lymph node

-

1 (1.8)

Alive

104 (90.4)

41 (74.5)

Dead

11 (9.6)

14 (25.5)

Site of metastatic lymph node
Recurrence
Disease-free survival (months)

Site of recurrence

Final situation

0.011
0.441

-

<0.001

Overall survival (months)

32.1 (1–83, median: 16)

26.4 (1–77, median: 19)

0.571

Median follow-up (months)

71.3 (1–182, median: 68)

60.8 (1–179, median: 53)

0.114
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Table 2. Recurrence sites with regard to lymph node status and adjuvant radiotherapy.
Recurrence site
Adjuvant
radiotherapy

Isolated
pelvic

Isolated
pulmonary

Upper
abdomen +
pulmonary

Pelvic + upper
abdomen +
pulmonary

Isolated
bone

Bone +
supraclavicular
lymph node

Bone +
pulmonary

Bone +
brain

Total

LN (-) + RT (-)

3

0

0

0

0

0

0

0

3

LN (-) + RT (+)

6

1

0

0

1

0

0

1

9

LN (+) + RT (+)

7

2

1

2

1

1

1

0

15

LN: Lymph node. RT: Radiotherapy.

nodes. In the lymph node-negative group that did not
receive adjuvant radiotherapy, there were 3 patients who
developed recurrences and all 3 recurrences were in the
pelvic region.
Recurrence and mortality were more common in
patients with lymph node metastasis (27.3% versus 10.4%,
P = 0.011 and 25.5% versus 9.6%, P < 0.001, respectively)
(Table 1). Time intervals from surgery to recurrence
and from surgery to death were approximately 6 months
longer in the lymph node-negative group; however, this
improvement was not statistically significant.

4–66 months. Recurrence occurred as an isolated pelvic
recurrence in 9 patients. In addition, isolated bone
recurrences were observed in 2 patients and isolated
pulmonary recurrence in 1 patient. One of the patients
who developed bone metastases also had brain metastasis
at the same time (Table 1). Death occurred in 11 cases of
recurrence, and the mean OS time was 32.1 months with a
range of 1–83 months. One of the patients who developed
an isolated pelvic recurrence underwent CCRT and
remained in remission during follow-up. Cell type of the
tumor for this patient was squamous cell carcinoma and
the tumor was LVSI positive and grade 1. The parametrium
and surgical margins were free of disease (Tables 3 and 4).

3.1. Development of recurrence
3.1.1. Lymph node-negative group
Tumor recurrence developed in 10.4% (n = 12) of the
lymph node-negative patients after initial treatment,
and the mean DFS rate was 25.2 months with a range of

3.1.2. Lymph node-positive group
In the lymph node-positive group, 85.5% of the patients
had isolated pelvic metastasis, 3.6% had isolated paraaortic

Table 3. Recurrence site and stage, histological diagnosis, and grade.
Recurrence site

Stage

Cell type

IB1

IB2

Squamous

Isolated pelvic

8

1

9

Isolated pulmonary

1

-

Isolated bone

1

Bone + brain

1

Isolated pelvic

Grade
Adenosquamous

Adenocarcinoma

1

2

3

-

-

2

7

-

1

-

-

-

1

-

-

1

-

-

-

-

1

-

1

-

-

-

1

-

6

1

5

1

1

1

6

-

Isolated pulmonary

2

-

2

-

-

1

1

-

Upper abdomen + pulmonary

-

1

-

1

-

-

1

-

Pelvic + upper abdomen + pulmonary

1

1

2

-

-

1

-

1

Isolated bone

1

-

1

-

-

-

1

-

Bone + supraclavicular lymph node

1

0

1

-

-

-

1

-

Bone + pulmonary

1

0

1

-

-

-

1

-

Lymph node-negative group

Lymph node-positive group
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Table 4. Recurrence site and surgical pathological factors.

Recurrence site

Parametrial invasion

Surgical margin
invasion

-

+

-

+

Isolated pelvic

8

1

9

-

Isolated pulmonary

1

-

1

-

Depth of stromal invasion
≤1/2

Lymphovascular space
invasion

Ovarian metastases

>1/2

-

+

-

+

2

7

6

3

9

-

-

1

-

1

1

-

Lymph node-negative group

Isolated bone

1

-

1

-

-

1

-

1

1

-

Bone + brain

-

1

1

-

-

1

-

1

1

-

5

2

6

1

2

5

-

7

6

1

Lymph node-positive group
Pelvic
Pulmonary

2

-

2

-

1

1

1

1

2

-

Upper abdomen + pulmonary

1

-

-

1

-

1

-

1

1

-

Pelvic + upper abdomen + pulmonary 1

1

1

1

-

1

-

2

2

-

Isolated bone

-

-

1

-

1

1

-

1

-

1

Bone + supraclavicular lymph node

1

-

1

-

-

1

-

1

1

-

Bone + pulmonary

1

-

1

-

-

1

-

1

1

-

metastases, and 10.9% had both pelvic and paraaortic
lymph node metastases. The mean number of involved
lymph nodes was 3.8 with a range of 1–19 nodes.
In this group, 27.4% (n = 15) of the patients
developed tumor recurrences after initial treatment. The
mean DFS rate was 18.8 months with a range of 3–51
months. Recurrence occurred as isolated pelvic disease
in 7 patients, isolated pulmonary disease in 2 patients,
simultaneous pulmonary and upper abdominal disease in
1 patient, and simultaneous pulmonary, upper abdominal,
and pelvic disease together in 1 patient (Table 3). In 3
patients, recurrences were detected as bone metastases.
Among the patients who developed bone metastases, 1
patient had a pulmonary recurrence and another patient
had supraclavicular lymph node involvement (Tables
1–3).
Lymph node status was not associated with the presence
of isolated pelvic recurrence or distant recurrence.
However, the frequency of distant metastases was 53.3%
(n = 8/15) in the lymph node-positive group and 25% (n
= 3/12) in the lymph node-negative group, which was not
statistically significant (P = 0.137). Pulmonary metastasis
was detected in only 1 of the lymph node-negative patients
who developed recurrences; however, 6 of the lymph nodepositive patients had pulmonary metastases. Similarly,
upper abdominal recurrences were observed in only the
lymph node-positive patients. The bone metastases were
similar in both groups (n = 2/12 versus 3/15).
3.2. Pelvic recurrence
All of the isolated pelvic recurrences in the lymph
node-negative group were squamous cell cancer (Table
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3). In contrast, 2 of 7 isolated pelvic recurrences in
the lymph node-positive group were adenocarcinoma
and adenosquamous carcinoma. Tumor recurrences
manifested as a combination of pelvic, upper abdominal,
and pulmonary metastases in 2 of the lymph node-positive
patients. In these patients, the histological cell type was
squamous cell carcinoma and 1 of the patients had a grade
3 tumor (Table 3). There were no grade 3 tumors in the
patients with isolated pelvic recurrences in both groups.
LVSI was positive in one-third of the lymph node-negative
patients, whereas all of the lymph node-positive patients
exhibited LVSI positivity (Table 4). LVSI was observed in
the patients who had a pelvic recurrence together with
upper abdominal and pulmonary metastases. Parametrial
and surgical margin involvement were negative in most of
the patients involved in the study (Table 4). The age, DFS,
OS, number of lymph nodes that were removed, and tumor
sizes were similar in both groups (P = 0.056, P = 0.352, P =
0.243, P = 0.195, P = 0.644, respectively) (Table 5). Only 1
of the patients in the lymph node-negative group who had
an isolated pelvic recurrence survived. All of the patients
in the lymph node-positive group who had an isolated
pelvic recurrence died (Table 6).
3.3. Pulmonary recurrence
In the lymph node-negative group, only 1 patient had an
isolated pulmonary recurrence of the squamous cell type.
The initial cancer in this patient was grade 2 and positive
for LVSI. In addition, depth of stromal invasion was
greater than ½ (Tables 3 and 4). Recurrence was detected
in the 66th month of follow-up, and the patient died in the
75th month of follow-up (Tables 5 and 6).

ÜREYEN et al. / Turk J Med Sci
Table 5. Recurrence site and demographic properties.
Age

Tumor size
(mm)

Number of removed
lymph nodes

Disease-free
survival (months)

Overall survival
(months)

Mean

55.1

32.8

50.3

24.9

37

Maximum

76

40

72

65

83

Minimum

45

20

30

4

12

Median

52

30

52

12

21

Isolated pulmonary (n = 1)

72

30

34

66

75

Isolated bone (n = 1)

69

30

51

6

9

Bone + brain (n = 1)

51

40

71

6

9

Mean

45.7

30.3

54.3

14.9

21.9

Maximum

52

52

79

36

40

Minimum

34

10

27

3

9

Median

48

30

48

14

19

Patient 1

50

30

59

15

20

Patient 2

34

20

52

6

17

50

55

50

36

77

73

40

44

51

58

Recurrence site
Lymph node-negative group
Isolated pelvic (n = 9)

Lymph node-positive group
Isolated pelvic (n = 7)

Isolated pulmonary (n = 2)
Upper abdomen + pulmonary
(n = 1)
Pelvic + upper abdomen +
pulmonary (n = 2)

Patient 1

50

40

22

6

8

Isolated bone (n = 1)

Patient 2

52

40

56

10

#

Bone + supraclavicular lymph node
(n = 1)

50

45

102

9

15

Bone + pulmonary (n = 1)

50

20

47

45

54

#: Alive without disease.

Table 6. Final situation after recurrence.
Recurrence site

Final situation
Alive

Dead

Isolated pelvic

1#

8

Isolated pulmonary

-

1

Isolated bone

-

1

Bone + brain

-

1

Isolated pelvic

-

7

Isolated pulmonary

-

2

Upper abdomen + pulmonary

-

1

Pelvic + upper abdomen + pulmonary

-

2

Isolated bone

1#

-

Bone + supraclavicular lymph node

-

1

Bone + pulmonary

-

1

Lymph node-negative group

Lymph node-positive group

#: Alive without disease.
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patients with isolated paraaortic lymph node metastases
had an isolated pelvic recurrence and the other patient had
an isolated pulmonary recurrence. Two of 3 patients with
pelvic and paraaortic lymph node metastases had distant
metastases.
In total, 25 patients with a recurrence died. One of the
patients who survived was in the lymph node-negative
group and had an isolated pelvic recurrence. The other
patient who survived was in the lymph node-positive
group and had an isolated bone recurrence. In the first
patient, recurrence was detected in the 42nd month of
follow-up and the patient underwent CCRT. The treatment
response was good, and the patient is still alive and without
disease. In the other patient, recurrence was detected in
the 10th month of follow-up and chemotherapy (cisplatin
+ 5-fluorouracil) was given. The treatment response was
good, and the patient is still alive and without disease.

Pulmonary recurrences were detected in 6 patients
who had positive lymph nodes. Among 6 patients
with pulmonary recurrences, 2 of them had isolated
pulmonary recurrences; 2 had pulmonary, pelvic, and
upper abdominal recurrences; 1 had pulmonary and
upper abdominal recurrences; and 1 had pulmonary
and bone recurrences. Five of these recurrences were
squamous cell carcinoma, and the remaining recurrence
was adenosquamous carcinoma (Table 3). None of the
pelvic recurrences were in the form of ovarian metastasis
among these patients. The mean DFS was 26.5 months
with a range of 6–51 months. The mean OS was 39 months
with a range of 8–77 months (Table 5). All of the patients
with a pulmonary recurrence died (Table 6). Detailed data
of the patients with pulmonary recurrences are featured in
Tables 1, 3, and 5.
3.4. Bone recurrence
Bone recurrences were observed in 5 of the patients, and all
of these recurrences were of the squamous cell type. Two
patients with negative lymph nodes had bone metastases.
One of these metastases was reported as isolated bone
metastases, whereas the other metastasis was reported as
bone and brain metastases. Both of the patients were given
adjuvant radiotherapy after the surgery. The recurrences
were detected in the 6th month of follow-up, and both of
the patients died in the 9th month of follow-up (Table 5).
In the lymph node-positive group, 1 patient had
isolated bone metastasis, another patient had bone and
pulmonary metastases, and the remaining patient had
bone and supraclavicular metastases. The DFS of the 3
patients in the lymph node-positive group were 10, 9, and
45 months, respectively. In this group, the patient with
isolated bone metastasis survived; however, the other 2
patients died (Table 6). The OS was 15 and 54 months for
these patients, respectively (Table 5).
3.5. Metastatic lymph node region and recurrence
Overall, 7 of 10 patients with isolated pelvic lymph node
metastases developed a pelvic recurrence and 5 of these
patients had an isolated pelvic recurrence. In 2 patients,
bone metastases were also reported (Table 7). One of 2

4. Discussion
To date, several reports have presented the prognostic
factors for cervical cancer. The major prognostic factors
that affect survival and recurrence are the stage, lymph
node status, tumor volume, depth of cervical stromal
invasion, lymphovascular space invasion, and, to a lesser
extent, histological type and grade. Lymph node metastasis
is one of the most important prognostic factors for cervical
carcinoma. Lymph node metastasis is an important route
by which cervical carcinoma can spread and relapse after
surgical treatment.
The pelvic lymph node metastasis rate in patients with
early-stage cervical cancer is 20%–25% (8,9). However,
Benedetti et al. reported that the rate of metastasis to any
lymphatic chain is approximately 36.2% (10). In this study,
pelvic lymph node metastases were detected in 27.6% of
the patients; pelvic and paraaortic lymph node metastases
were detected in 32% of the patients.
Lymph node metastasis was an independent prognostic
factor (11–17). However, in a univariate analysis of patients
with positive lymph nodes, Rutledge et al. reported
that 2-year DFS decreases from 89% to 63%, whereas a

Table 7. Recurrence localization of lymph node-positive patients with the effect of the positive lymph node area.
Recurrence site
Metastatic lymph
node area
Isolated pelvic

Isolated
pelvic

Isolated
pulmonary

Upper abdomen
+ pulmonary

Pelvic +
upperabdomen
+ pulmonary

Isolated
bone

Bone +
supraclavicular
lymph node

Bone +
pulmonary

Total

5

1

-

2

1

-

1

10

Isolated paraaortic

1

1

-

-

-

-

-

2

Pelvic + paraaortic

1

-

1

-

-

1

-

3
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multivariate analysis did not demonstrate this prognostic
effect (18). Metindir et al. reported that lymph node
involvement does not affect the 5-year DFS rate (19). In
this study, the prognostic factors for cervical cancer were
not studied. However, when the data were evaluated in a
univariate analysis, the determinative impact of the lymph
node status on the survival rate was indicated. Following
radical surgery, patients with early-stage cervical cancer
have a recurrence rate of 10% and a mortality rate of 10%
in the presence of negative lymph nodes. In the presence
of lymph node metastasis, the recurrence rate is 27% and
the mortality rate is 25%.
The prognostic role of nodal involvement in primary
cervical cancer is maintained when recurrence is
detected; however, lymph node status did not significantly
correlate with the presence or absence of distant failure
in our study. In the study group, 6 of 7 patients with
pulmonary recurrences had lymph node metastases. In
addition, an upper abdominal recurrence was detected
only in the lymph node-positive group. Additionally,
in the group with negative lymph nodes, distant failure
was observed only in the patients who received adjuvant
radiotherapy. These patients had a high risk of recurrence.
In this group, pelvic recurrence was observed in only
5.2% of the patients who did not receive radiotherapy.
This finding may indicate the need for new treatment
modalities, which would include systemic chemotherapy,
in patients who require adjuvant radiotherapy following
radical hysterectomy. In the Cochrane Review, Rosa et
al. recently reported that the addition of platinum-based
chemotherapy to adjuvant radiotherapy may improve
survival in women with early-stage cervical cancer and
reduce the risk factors for recurrence (20). Another study
by Hosaka et al. revealed that postoperative chemotherapy
using paclitaxel/cisplatin may be more beneficial for
survival than adjuvant radiotherapy and could reduce
postoperative complications for cervical cancer patients
who are treated with radical hysterectomy (21).
In this study, the disease recurred as bone metastases
(isolated or included other regions) in 5 of 27 patients
with recurrences. In all of these patients, the histological
diagnosis was squamous cell carcinoma and all of these
patients were given adjuvant radiotherapy after surgery.
Interestingly, the disease recurred earlier and the OS was
less than 1 year in 2 patients with negative lymph nodes
who developed bone metastases. However, in the lymph
node-positive group, 1 patient responded to salvage therapy
and the survival was significantly higher in 2 patients
(15 and 54 months). The frequency of bone metastases
ranges from 0.8% to 1.9% in cervical cancer (22–24). The
histological diagnosis is generally the squamous cell type
(23). Radiotherapy alone or CCRT has no effect on the
recurrence of disease in the form of bone metastases (25).

Demographically, the ages of the patients in the 2
groups were similar. Patients with an isolated pelvic
recurrence with positive lymph nodes were 10 years
younger than the patients with isolated pelvic recurrence
with negative lymph nodes (45.7 years versus 55.1 years)
(Table 5). However, this result was not statistically
significant (P = 0.056). According to the DFS and OS,
patients with negative lymph nodes improved by 6 months
compared with those with positive lymph nodes. However,
this 6-month improvement in the survival rate was not
statistically significant; that may be due to the relatively
small size of the study population. Improvement was
significant in patients with an isolated pelvic recurrence,
and patients with negative lymph nodes had a 10-month
increase in the DFS and a 15-month increase in the OS.
However, this difference between the lymph node-negative
and lymph node-positive cases was also not statistically
significant (P = 0.352, P = 0.243, respectively). In the
lymph node-negative group, 1 of the isolated pulmonary
recurrences was detected in the 66th month of followup. However, in the lymph node-positive group, 2 of the
isolated pulmonary recurrences were detected sequentially
in the 6th and 15th months of follow-up. Isolated pelvic
and pulmonary recurrences were detected later in the
lymph node-negative group; however, our patient group
included a limited number of cases.
In our study, the mortality rate was 95.6% in the
recurrence group. In each group, 1 patient survived. These
2 patients had an isolated recurrence and both patients
responded to salvage therapy.
In this study, we found clinically significant differences
that did not reach statistical significance. This may be due
to the relatively small size of the study population. Another
limitation of the study was that it was retrospective.
In conclusion, the probability of recurrence in cervical
cancer increases in cases of lymph node metastasis. In
addition, distant recurrences are more prominent in lymph
node-positive patients. Among the lymph node-negative
patients, three-fourths of all recurrences were central
recurrences. In this group, distant failure was observed
in the patients who received adjuvant radiotherapy.
Consequently, systemic chemotherapy may be considered
for the prevention of distant failure in patients who require
adjuvant radiotherapy following radical hysterectomy. In
this situation, a new treatment model should be considered.
Therefore, a prospective evaluation of surveillance
programs is required to determine an evidence-based
follow-up strategy for patients with cervical cancer.
More prospective studies that are aimed at elucidating
the recurrence patterns of cervical cancer can provide
an evidence-based follow-up strategy for patients with
cervical cancer.
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